General Comments & Additional Information
Clinical Info: NORMAL REPORT

Ordered Items
Rivaroxaban

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rivaroxaban</td>
<td>33.5</td>
<td>01</td>
<td>ng/mL</td>
<td></td>
<td>01 BN LabCorp Burlington</td>
</tr>
</tbody>
</table>

Plasma concentrations of rivaroxaban following once daily dosing were as follows (12):
10 mg (Once Daily) Dose:
Mean Peak 124.6 91.4 - 195.5
Trough 9.1 1.3 - 37.6

20 mg (Once Daily) Dose:
Peak 222.6 159.6 - 359.8
Trough 22.3 4.3 - 95.7

Peak levels should be drawn 3 hours after oral dosing. Trough levels are drawn 24 hours after oral dosing. Steady state is attained after 4 to 6 days of once daily treatment. The peak and trough ranges were obtained from the following study and represent the median (5th and 95th percentiles). The 10 mg dose study included 135 patients and the 20 mg dose study 131 patients.


Comments:
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
**Clinical Info:** ABNORMAL REPORT

**Ordered Items**
Rivaroxaban

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rivaroxaban A</td>
<td>450.8</td>
<td>01</td>
<td>ng/mL</td>
<td></td>
<td>LabCorp Burlington</td>
</tr>
</tbody>
</table>

Plasma concentrations of rivaroxaban following once daily dosing were as follows (12):

10 mg (Once Daily) Dose:
- Mean Peak: 124.6
- Mean Trough: 9.1
- Range (+/- 2SD): 91.4 - 195.5
- Range (1.3 - 37.6)

20 mg (Once Daily) Dose:
- Peak: 222.6
- Trough: 22.3
- Range (59.6 - 359.8)
- Range (4.3 - 95.7)

Peak levels should be drawn 3 hours after oral dosing. Trough levels are drawn 24 hours after oral dosing. Steady state is attained after 4 to 6 days of once daily treatment. The peak and trough ranges were obtained from the following study and represent the median (5th and 95th percentiles). The 10 mg dose study included 135 patients and the 20 mg dose study 131 patients.


**Comments:**

A This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.